Naptumomab estafenatox - Active Biotech/NeoTX Therapeutics
Alternative Names: ABR-217620; Anyara; NAP - Active Biotech/NeoTx Therapeutics; NTX 352; TTS CD3Latest Information Update: 21 Jul 2024
At a glance
- Originator Active Biotech
- Developer Active Biotech; AstraZeneca; NeoTX Therapeutics
- Class Antineoplastics; Drug conjugates; Fab fragments; Immunotherapies; Immunotoxins; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I/II Solid tumours
- Phase I Oesophageal cancer
- Suspended Pancreatic cancer; Renal cancer
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase-II clinical trials in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 11 Apr 2024 NeoTX Therapeutics and Weill Medical College of Cornell University withdraw a phase I trial in Urogenital cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) prior to enrollment due to insufficient funds (NCT05894447)
- 28 Mar 2024 Phase-I clinical trials in Oesophageal cancer (IV) (NeoTX Therapeutics pipeline, July 2024)